Epidemiology Study of Keloid

NCT01423383 — Unknown, 100000 participants, Tirgan, Michael H., M.D.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT01423383
StatusUnknown
Study typeObservational
Enrollment100000 (Estimated)
SponsorTirgan, Michael H., M.D. (Indiv)
ConditionsKeloid
Datesstart 2011-09-01, primary completion 2020-06-01 (estimated), completion 2021-12-01 (estimated), first posted 2011-08-25, last updated 2016-10-18
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Keloid

-Summary

Although keloid is a very common condition; there are no statistics as to its true incidence and prevalence, neither in United States, nor elsewhere in the world. This trial intends to capture epidemiological data about this disease in a large population sample.

Expand all sections  ·  Collapse all

+Detailed description

The purpose of current trial is to establish a robust database of incidence and prevalence of keloid, as well as prevalence of familial keloid, in various ethnic groups. Study sample size is 100,000 random individuals who will fill out either a web survery or a paper questionnaire.

+Arms and interventions

ArmTypeInterventionsDescription
Random PopulationsThe aim of this study is to determine the prevalence and incidence of keloid in large populations.

+Outcome measures

Primary outcomes

  • Prevalence of various clinical findings will be determined at the end of Survey. [Two Years]: This will be a prospective online and paper based survey with an estimated 100,000 responders participating in two years. Statistics will be descriptive. The prevalence of various clinical findings will be determined at the end of Survey. Findings will be correlated with the source of the data, online, or paper questionnaire, as well as the locations where the paper questionnaires surveys were placed.

+Eligibility

Sex: All, accepts healthy volunteers

Inclusion Criteria:

1. Informed consent
2. Age above 18 to answer the survey questions
3. Parents shall respond on behalf of their minor children

Exclusion Criteria:

* None

+Locations (1)

FacilityCityCountryStatus
Michael H. Tirgan, MDNew York, New YorkUnited StatesRecruiting

+Investigators